Skip to content

Search

Back to school anxiety: How to help your child transition into the new school year

As we count down to the end of the long summer holidays, it’s natural for children to feel anxious about what the new school year will bring.

The National Allergy Centre of Excellence–Addressing Australia's Allergy Burden

Australia has one of the highest rates of food allergy, anaphylaxis hospital admissions and anaphylaxis fatalities worldwide. These trends and sustained advocacy prompted a 2019 Parliamentary Inquiry into Allergies and Anaphylaxis. Among 250 submissions, the Centre for Food Allergy Research called for a national research-coordinating centre and comprehensive allergy research funding.

ASCIA Guideline: Infant Feeding for Food Allergy Prevention

The Australasian Society of Clinical Immunology and Allergy (ASCIA) Guideline: Infant Feeding for Food Allergy Prevention is an update of the 2016 ASCIA guideline. This updated guideline provides recommendations specifically in relation to infant feeding for food allergy prevention. 

Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program

Peanut allergy is the most common food allergy in Australian school-aged children and is rarely outgrown. Access to oral immunotherapy (OIT), a disease-modifying treatment for food allergy, is limited in many regions of the world, including Australia.

Nuts For Babies Study: protocol for a randomised controlled trial in Australia

The predisposition to food allergy development and the induction of allergen-specific immune responses appears to be initiated early in infancy. Early exposure to food allergens, such as peanut and cashew nut, via human milk is likely important in initiating oral tolerance and reducing risk of food allergy development. This trial aims to determine if the risk of developing peanut and cashew nut allergy during infancy can be reduced by a high peanut and cashew nut maternal diet during lactation.

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE

The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.

Allergen Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years

Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely cor

Mechanisms of allergic disease - environmental and genetic determinants for the development of allergy

Environmental exposures including maternal inflammation, diet, nutrient balance, microbial colonization and toxin exposures can directly and indirectly...

Prevention and Natural History of Food Allergy

The rise in food allergy is more rapid than genetic deviation would allow and the current consensus is that environmental factors integrally linked to the...

Developing primary intervention strategies to prevent allergic disease

Allergic diseases are a major cause of morbidity in the developed world, now affecting up to 40 % of the population with no evidence that this is abating.